CD160 Expression in Corneal Vessels
CD160 Ans Corneal Graft: Expression in Corneal Vessels
1 other identifier
observational
43
1 country
1
Brief Summary
Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 21, 2021
CompletedFirst Submitted
Initial submission to the registry
August 3, 2021
CompletedFirst Posted
Study publicly available on registry
August 17, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 22, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 22, 2025
CompletedFebruary 19, 2026
February 1, 2026
4.7 years
August 3, 2021
February 17, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Micro-vascular densities
neovascularization scores quantification of blood (anti-ERG+/anti-D2-40-) and lymphatic (anti-ERG+/anti-D2-40+) vascular structures ; Percentages of those vascular structures marked with anti-CD160
1 year
Secondary Outcomes (2)
Percentages of those vascular structures marked with anti-CD160 and/or CD105 and/or aSMA
1 year
Evaluation of clinical blood vascular densities on photographs with help of ImageJ software
1 year
Study Arms (2)
HOSTS
patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor
DONORS
grafts from donors that would be analyzed
Interventions
Immunohistochemistry and clinical analyses on patients and corneas
Eligibility Criteria
18-year-old or more patients enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France
You may qualify if:
- year-old or more patients
- enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France
You may not qualify if:
- none
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- CHU de Reimslead
Study Sites (1)
Damien JOLLY
Reims, France
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 3, 2021
First Posted
August 17, 2021
Study Start
April 21, 2021
Primary Completion
December 22, 2025
Study Completion
December 22, 2025
Last Updated
February 19, 2026
Record last verified: 2026-02